9 Important is histotype-selective activity of pemetrexed, with a significant benefit seen only in patients with non-squamous-cell lung cancer, 10 potentially as a consequence of increased TYMS expression in tumors of squamous histology.
Given the loss of statistical significance upon further regression analysis and the benefit seen only after 28 days, the small difference in 90-day mortality that initially emerged in the subgroup analysis of patients with septic shock is very likely due to chance.
Although there was an overall benefit on mortality (OR 0.52, 95% CI 0.36 to 0.74; P = 0.003), subgroup analyses revealed that mortality benefit was seen only in studies that included extremely high risk patients (OR 0.20, 95% CI 0.09 to 0.41; P < 0.0001) but not for the intermediate-risk patients (OR 0.83, 95% CI 0.41 to 1.69; P = 0.62).
The benefit was seen only in the first year after the completion of chemotherapy.
Another important finding was that the benefit was seen only in hormonal-receptor-negative disease.
Predefined subgroup analysis according to the timing of GDT for resuscitation suggested that a mortality benefit was seen only in the subgroup of early GDT within the first 6 hours (seven trials; RR, 0.77; 95% CI, 0.67 to 0.89; P =0.0004; I = 40%), but not in the subgroup with late or unclear timing of GDT (six trials; RR, 0.92; 95% CI, 0.69 to 1.24; P =0.59; I = 56%).
Predefined subgroup analysis according to the timing of GDT for resuscitation suggested that a mortality benefit was seen only in the subgroup in early GDT within the first 6 hours (seven trials; RR, 0.77; 95% CI, 0.67 to 0.89; P =0.0004; I = 40%), but not in the subgroup with late or unclear timing of GDT (six trials; RR, 0.92; 95% CI, 0.69 to 1.24; P =0.59; I = 56%).
Last week, 427,000 people filed new claims for jobless benefits, a level typically seen only during recessions.
The PFS benefit from bortezomib could be seen only in younger patients but not in older ones; the median PFS was 38 and 25 months (P<0.001), respectively, in younger patients who received bortezomib and those who did not.
When we analyzed by age, the PFS benefit from bortezomib could be seen only in younger patients but not in older ones; the median PFS was 38 and 25 months (P=0.00), respectively, for younger patients who received bortezomib compared with those who did not.
Because the benefits of educational investments are seen only in the future, it is possible to underestimate the value and the importance of improvements.
